Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

JPM19

- PMLiVE

First UK cancer patients receive Moderna’s experimental mRNA therapy

The Mobilize trial is evaluating mRNA-4359 in cancers including melanoma and lung cancer

- PMLiVE

Moderna and CEPI enter pandemic preparedness partnership

The partnership aims to expand infectious disease targets for mRNA vaccine technology

- PMLiVE

Moderna’s COVID-19/flu combination vaccine shows promise in phase 1/2 study

The approach could simplify immunisation practices and lead to higher vaccine uptake

- PMLiVE

Moderna’s XBB.1.5-adapted COVID-19 vaccine receives MHRA approval

The vaccine has been updated to target the currently circulating XBB.1.5 Omicron variant

- PMLiVE

Moderna shares positive phase 3 results for mRNA influenza vaccine candidate

mRNA-1010 generated a strong immune response against all four WHO-recommended flu strains

- PMLiVE

Moderna and Immatics announce oncology collaboration worth over $1.7bn

The agreement will focus on the development of bispecifics, cell therapies and cancer vaccines

- PMLiVE

FDA approves Pfizer/BioNTech and Moderna’s updated COVID-19 vaccines

The vaccines have both been adapted to target the currently circulating XBB.1.5 Omicron variant

- PMLiVE

Moderna’s updated COVID-19 vaccine shows strong effect against BA.2.86 subvariant

The ‘highly mutated’ BA.2.86 subvariant is being closely monitored by global health authorities

- PMLiVE

Moderna and Merck’s skin cancer vaccine enters late-stage development

More than 1,000 patients with resected high-risk melanoma will be enrolled in the trial

- PMLiVE

Moderna and IBM to explore quantum computing and AI for future mRNA medicines

A growing number of biopharmas have been investing in quantum computing over recent years

- PMLiVE

Authorisation for Moderna and Pfizer/BioNTech’s bivalent COVID-19 vaccines simplified by FDA

The vaccines are now authorised for all doses in individuals aged six months and older

- PMLiVE

Moderna/Merck’s cancer vaccine shows promise in high-risk melanoma patients

Nearly 325,000 new cases of melanoma were diagnosed globally in 2020

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links